Introduction
Head and neck squamous cell carcinoma (SCCHN) represents approximately 6% of all new cancers in the United States (Hughes and Frenkel, 1997; Chikamatsu et al., 1999; Khurana et al., 2001) . Despite changes in treatment strategies, prognosis for patients with SCCHN has not improved significantly in more than 30 years, with the 5-year survival remaining at 50-60% (Hughes and Frenkel, 1997; Simon et al., 1998; Chikamatsu et al., 1999; Khurana et al., 2001) . Improvement in survival will likely result from better understanding of the molecular alterations that underlie the pathophysiology of SCCHN.
Multiple genetic abnormalities have been reported in SCCHN including amplifications and overexpression of EGFR, Cyclin D1 and loss of tumor suppressor genes including p53, p16, p21 and retinoblastoma (Gleich and Salamone, 2002; Lai et al., 2002; Hardisson, 2003) . The expression of heparin-binding growth factors such as fibroblast growth factor (FGF-2), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF) and heparin-binding epidermal growth factor is also altered in SCCHNs (Modjtahedi and Dean, 1995; Dong et al., 2001; Fleigel et al., 2002; Katoh, 2002; Riedel et al., 2002; Vlachtsis et al., 2002) . Ongoing intensive investigations are likely to define critical checkpoints for growth factor signaling in SCCHN.
It is now clear that HS-GAGs serve as key regulatory checkpoints in heparin-binding growth factor signaling. The best example of such a regulation is the role of HSGAGs in FGF-2 signaling (Lundin et al., 2000; Delehedde et al., 2002) . FGF-2 binding to its receptors FGFR and heparan sulfate proteoglycans (HSPGs) promotes the formation of a ternary complex that is essential for cell proliferation and angiogenesis. Sulfation of specific sites on the HS-GAGs is critical for this interaction. The interaction of FGF-2 with FGFR and HS-GAGs leads to receptor dimerization, activation and autophosphorylation followed by activation of downstream signaling pathways, including the mitogen-activated protein kinase (MAPK) pathway. While there are no reports of the involvement of FGF-2 leading to the activation of ERK in SCCHN, the increased expression of FGF-2 and FGFR2 in SCCHN is frequently reported (Riedel et al., 2000; Wakulich et al., 2002) . These findings allude to the role that FGF-2 may play in squamous cell carcinoma of the head and neck. While ERK/MAPKs is postulated to be important for cell proliferation, very little is known about the involvement of activated ERK in SCCHNs by FGF-2.
Like FGF-2, HGF is also postulated to play an integral role in the uncontrolled growth of solid tumors. HGF (also known as scatter factor) is a stromal-derived pleiotropic polypeptide, and its receptor c-Met is expressed in a variety of human cancers including SCCHN (Dong et al., 2001) . C-Met ligation by HGF triggers the catalytic tyrosine kinase domain that activates MEK and PI3K signal pathways contributing to the expression of proangiogenic factors IL-8 and VEGF (Dong et al., 2001) . While the overexpression of heparin-binding HGF and c-Met is associated with tumor metastasis and angiogenesis (Dong et al., 2001; Zeng et al., 2002) , the mechanisms underlying these effects remain unclear. HGF has the capacity to mediate 'invasive growth', a hallmark of metastasis, due to coordinated activity of cell motility, the degradation of extracellular matrix ultimately leading to invasiveness and metastasis (Matsumoto et al., 1994; Galeazzi et al., 1997) . While HGF-mediated activation of ERK is postulated to be important for tumorigenesis, there is a paucity of information on the activation of ERK mediated through FGF-2 signaling in SCCHN.
We recently reported on the functional consequences of the loss of HSulf-1, a sulfatase with a high degree of homology with human lysosomal N-acetylglucosamine 6-sulfatase in ovarian cancer in modulating heparinbinding growth factor signaling (Lai et al., 2003) . The purpose of the present study was to evaluate whether HSulf-1 downregulation was a common mechanism by which SCCHN cells overcome the key regulatory checkpoint in heparin-binding growth factor signaling. Here, we report for the first time that HSulf-1 expression results in the downregulation of both FGF-2-and HGFmediated activation of both ERK and PI3K/Akt pathways with a resultant decrease in proliferation and mitogenecity in vitro. More importantly, HGF-mediated cell motility and invasiveness was attenuated in HSulf-1 clonal 012SCC cell lines. In addition, HSulf-1 expression increases the sensitivity of SCCHN cells lines to staurosporine-and cisplatin-induced apoptotic cell death. Collectively, these data indicate that loss of HSulf-1 in SCCHN serves as a regulatory event, which is involved in the activation of survival pathways mediated through these two important kinase cascades.
Results

HSulf-1 expression in SCCHN cell lines
Semiquantitative RT-PCR with primers Sulf 3F and 3R revealed complete absence of the expression of HSulf-1 transcript in all three SCCHN cell lines compared to a normal squamous epithelial control from the head and neck region from a patient with no signs of cancer ( Figure 1a) . To assess the functional consequences of the loss of HSulf-1 expression in SCCHN cell lines, full-length (FL) HSulf-1 cDNA was transfected into the 012SCC cell line and we isolated two stable clones, HSulf-1-1-and HSulf-1-2-expressing HSulf-1 (Figure 1b HSPGs detected with sulfation-specific antibody. 012SCC parental cells and the indicated stable, cloned transfectants were fixed and stained for sulfated HS-GAG using antibody 10E4, which recognizes native heparan sulfate with N-sulfated glucosamine residues (upper) or antibody 3G10, which recognizes deglycosylated HS-GAGs (lower) sulfatase activity, we measured the sulfatase activity with the flourogenic substrate 4-MUS in the presence of the estrone sulfatase inhibitor EMATE as described in the Materials and methods. There was an increase in the sulfatase activity in 012SCC HSulf-1-1 and HSulf-1-2 clones compared to the vector-transfected control ( Figure 1c ). This activity was comparable in stably transfected HSulf-1 clones of ovarian cancer cell lines as reported previously (Lai et al., 2003) .
FGF-2 signaling
Similar to our previous report that HSulf-1 localizes to the cell surface and desulfates HS-GAGs (Lai et al., 2003) , using sulfation-specific antibodies, we saw that HSulf-1 regulates HSPG sulfation also in SCCHN cells (Figure 1d ). To explore the role that desulfation of cell surface HS-GAGs by HSulf-1 plays in cellular growth control, we investigated the effect of HSulf-1 expression on FGF-2 signaling in SCCHN cell lines. Treatment of 2 ng/ml FGF-2 for 15 and 60 min resulted in a sustained ERK phosphorylation in vector-transfected clone, but a significant downregulation in HSulf-1-expressing 012SCC clones 1 and 2 ( Figure 2a ). Transient transfection of WMMSCC cells with FL-HSulf-1 dampened FGF signaling as assessed by the activation of ERK p42/44, whereas mutation of two conserved cysteines at the active site of the sulfatase domain only construct abrogated this modulation ( Figure 2b ). This is similar to what we observed in ovarian tumor cell lines (Lai et al., 2003) .
HSulf-1 modulates HGF-mediated ERK and PI3K/Akt signaling
Since the heparin-binding HGF-mediated signaling seems to play an important role in head and neck cancer, we sought to determine whether HSulf-1-expressing SCCHN clones modulated signaling by HGF. Treatment of 5 ng/ml HGF for 15 and 60 min resulted in a sustained c-Met phosphorylation in a vector-transfected 012SCC clone, but a significant downregulation in HSulf-1 expression 012SCC clones 1 and 2 ( Figure 3a , panel 1). This downregulation was reflected in the activation of both Akt (Figure 3a , panel 3) and ERK phosphorylation ( Figure 3a , panel 5) in HSulf-1-expressing clones. Total c-Met, total Akt and total MAPK served as loading controls ( Figure 3a , panels 2, 4 and 6, respectively).
HSulf-1 inhibits cell proliferation and mitogenesis
In order to assess whether this modulation would reflect in decreased cell proliferation and DNA synthesis, we determined cell proliferation using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT assay) and [ 3 H]thymidine incorporation, respectively. 012SCC-HSulf-1 clones 1 and 2 proliferated more slowly compared to vector-transfected control ( Figure 3b ). This decrease in cell number of 012SCC HSulf-1-expressing clonal lines was reflected in a decrease in DNA synthesis ( Figure 3c ).
HSulf-1 inhibits HGF-mediated motility and invasion
In order to determine whether this inhibition of Akt activation was reflected in a change in the motility or invasion, we first evaluated change in the motility of vector-transfected and HSulf-1 012 SCC clones 1 and 2 with and without HGF. Addition of 40 ng/ml HGFinduced motility was significantly decreased in both HSulf-1-expressing 012SCC clones compared to the vector-transfected control (Figures 4a and b) . Similar results were obtained when Matrigel invasion assay was performed. The HSulf-1 012SCC cells showed less ability to invade the basement membrane even in the presence of HGF compared to vector-transfected controls (Figures 4c and d ).
HSulf-1 modulates staurosporine-mediated apoptosis
To examine the effects of HSulf-1 re-expression on apoptosis, stable transfectants were treated for 5 h with 1 mM straurosporine, a broad-spectrum kinase inhibitor (Gescher, 2000) that is widely used as a prototypic proapoptotic stimulus because it induces apoptosis in a wide variety of cells. Cells were then stained with DAPI and examined for apoptotic morphological changes (nuclear fragmentation and condensation) by fluorescence a b Figure 2 (a) HSulf-1 modulates FGF-2 signaling in the 012SCC cell line. The indicated cells were cultured in serum-free medium for 8 h, then treated with 2 ng/ml FGF-2 for 15 and 60 min. Whole-cell lysates were subjected to SDS-PAGE, transferred onto nitrocellulose and sequentially probed with antisera that recognize antiphospho-ERK1/2 and total MAPK. FGF-2 induced sustained phosphorylation of ERK1/2 in vector-transfected cells, but not HSulf-1-expressing clones. (b) An active sulfatase domain is required to modulate signaling. WMMSCC cells were transfected with cDNA encoding the N-terminal domain of HSulf-1 or an N-terminal domain-containing cysteine-alanine mutations of two conserved cysteines in the sulfatase domain (Mut-N-Sulf). Cells were incubated for 15 min with 2 ng/ml FGF-2. Phosphorylation of ERK1/2 was decreased in cells transfected with the N-Sulf construct, but not the mutant construct HSulf-1 modulates HGF signaling in head and neck cancer J-P Lai et al microscopy. The results of this analysis indicated that staurosporine induced little apoptosis in parental-or vector-transfected cells under these conditions. In contrast, staurosporine induced apoptosis in 40% of HSulf-1-transfected cells (Figure 5a ). Similar results were observed in WMMCC cells transiently transfected with the FL-HSulf-1 construct, compared to parentalor vector-transfected controls (Figure 5b ). To confirm that this modulation of apoptosis reflected the sulfatase activity of HSulf-1, 012SCC and WMMSCC cells were transiently transfected with a C-terminal truncation construct (N-Sulf) and active site mutant (Mut-N-Sulf). Transfection with the N-terminal fragment containing the entire sulfatase domain (N-Sulf) enhanced the ability of staurosporine to induce apoptosis. Importantly, sitedirected mutagenesis of the putative catalytic cysteines C 87 and C 88 in N-Sulf-1 (Mut-N-Sulf-1) abolished the ability of HSulf-1 to modulate apoptosis (Figures 5a and  b) , providing evidence that sulfatase activity is required for this modulation. HSulf-1 by itself did not induce apoptosis, but instead modulated the sensitivity of cells to other stimuli. These results were confirmed by flow cytometry by 7-aminoactinomycin D (7AAD) staining in vector and HSulf-1-1 012SCC (Figure 5c ) and transiently transfected WMMSCC cells (data not shown) as compared to 012SCC and WMMSCC parental or vector-transfected cells.
HSulf-1 modulates cisplatin-induced apoptosis
To determine whether HSulf-1 modulated apoptosis induced by cisplatin, the most commonly used drug to treat SCCHN patients, 012SCC HSulf-1 clones 1 and 2 were treated with 5 mM cisplatin for 24 h and % apoptosis was determined as described. HSulf-1 modulated the apoptosis induced by cisplatin and the extent of apoptosis correlated with the levels of HSulf-1 expression (Figure 5d ).
Discussion
In a previous study, we reported the downregulation of HSulf-1 in several tumor cell lines including ovarian, breast, kidney, pancreatic and hepatocellular carcinomas, and its involvement in modulating heparin-binding growth factor signaling in ovarian cancer. In the present study, our findings demonstrate that HSulf-1 was also lost in three head and neck cancer cell lines 012SCC, 015SCC and WMMSCC, but expressed in a normal tissue derived from the head and neck.
HSPGs are found at the surface of virtually every cell type, where they act as important biological mediators of cellular events such as proliferation, morphogenesis, adhesion, migration and apoptosis. The ability of HSPGs to regulate a variety of cellular processes is due both to structural and chemical diversity of the HS-GAG polymer (Liu et al., 2002; Sasisekharan et al., 2002) . that FGF-2 binds to its receptor and to HSPGs, which act as coreceptors and promote the formation of a ternary complex that is essential for cell proliferation and angiogenesis. As indicated in the introduction, previous reports have also demonstrated that sulfation of specific sites on the HS-GAGs is critical for this interaction. Like the receptors for FGFs, the HGF receptor c-Met also binds tightly to HS-GAGs (Rubin et al., 2001) . The studies demonstrating the interaction of HGF with heparan sulfate are limited. However, the structural specificity of the HGF-HS interaction using HGF-binding oligosaccharides revealed the requirement of 6-O-sulfation of the glucosamine-6-sulfate residues than with sulfation at any other position (Lyon et al., 1994) . Studies by Morimoto-Tomita et al. (2002) indicated that HSulf-1 exhibits sulfatase activity with a preference for glucosamine-6-sulfate substrates, implicating HSulf-1 as one of the critical enzymes disrupting this interaction. Thus, our present studies extend our earlier results (Lai et al., 2003) demonstrating that HSulf-1 reexpression, which diminishes cell surface HS-GAG sulfation, interferes with both FGF-2 and HGF signaling in SCCHN. Consistent with these results, we have demonstrated that desulfation of cell surface HS-GAGs by HSulf-1 in SCCHN (Figure 1d ) plays an important role in cellular growth control. FL HSulf-1-and N-terminal HSulf-1-transfected WMMSCC cells showed significantly less p42/44 MAPK phosphorylation in response to FGF-2 treatment than parental WMMSCC, vector or active site mutated N-terminal HSulf-1 constructs. Thus, HSulf-1 expression attenuates FGF-2 signaling through the MAPK pathway.
As sustained ERK phosphorylation has been implicated in proliferation (Bhalla et al., 2002) as well as resistance to apoptosis (Bonni et al., 1999; Dent and Grant, 2001 ), we next examined the effect of HSulf-1 reexpression on these processes. Our MTT assay confirmed that HSulf-1-transfected SCCHN cells grow significantly slower than vector-transfected or parental SCCHN cells. This attenuated growth is due to a decrease in DNA synthesis as evidenced by a 60% reduction in Motility (a and b) and invasion (c and d) assays were performed in transwell chamber with porous membrane. In both experiments, after 6 h serum starvation, the cells were seeded on the upper side of the filter and recombinant HGF in serum-free media was added to the lower chambers. In control wells, serum-free media alone were added. Cells that migrated to the filter lower side were stained, photographed and counted. HSulf-1 modulates HGF signaling in head and neck cancer J-P Lai et al HSulf-1-expressing cells do not undergo enhanced apoptosis compared to vector or parental nonexpressing cells. We therefore investigated the effect of HSulf-1 expression on the sensitivity of SCCHN cells to apoptosis induced by staurosporine, a stimulator of apoptosis and cisplatin, a drug commonly used to treat SCCHN patients. We assessed apoptosis in 012SCC cells stably transfected with plasmids expressing either the FL sulfatase domain (HSulf-1) or sulfatase domaincontaining N-terminal region of HSulf-1 (012SCC-NSulf-1 and WMMSCC-N-Sulf1) or sulfatase domaincontaining N-terminal region mutated HSulf-1-1 (012SCC-Mu-N-Sulf-1 and WMMSCC-Mu-N-Sulf-1). 012SCC-HSulf-1-1, 012SCC-N-Sulf-1, WMMSCCHSulf-1 and WMMSCC-N-Sulf-1 showed high sensitivities to staurosporine-induced apoptosis. In contrast, 012SCC-Mu-N-Sulf-1 and WMMSCC-Mu-N-Sulf-1 cells showed minimal sensitivity to staurosporineinduced apoptosis, similar to the HSulf-1-negative parental 012SCC and WMMSCC. These results are consistent with the hypothesis that inactivation of HSulf-1 increases the sulfation state of SCCHN cell surface HS-GAGs, resulting in increased cellular survival signaling by growth factors and decreased sensitivity of SCCHN to apoptosis. Re-expression of HSulf-1 decreases the sulfation state of HS-GAGs and abrogates growth factor signaling, making the cell sensitive to apoptotic stimuli such as staurosporine. HSulf-1 also modulated apoptosis induced by cisplatin.
The effect of HSulf-1 expression was not limited to FGF-2. HSulf-1 also modulated downstream signaling mediated by another heparin-binding growth factor, HGF in SCCHN. On treatment with 5 ng/ml HGF, the HSulf-1-expressing 012SCC clones not only downregulated the activation of ERK but also attenuated the activation of phospho-Akt. More importantly, the ability of cancer cells to invade and metastasize, which are hallmarks for cancer progression, was significantly inhibited in HSulf-1-expressing cells.
The c-MET oncogene encodes the receptor for HGF/ scatter factor (HGF/SF), which is known to stimulate the invasive growth of epithelial cells cultured in vitro. The overexpression of Met/HGF receptor was found in all tumor stages, but was significantly associated with enlarged or multiple (N2-N3) lymph node metastasis (Galeazzi et al., 1997) , and the authors speculated that (Rong et al., 1994; Jeffers and Woude, 1996) . As c-Met-HGF signaling is clinically associated with metastasis in SCCHN cells (Matsumoto et al., 1994; Cortesina et al., 2000) , we performed experiments to determine whether HSulf-1 provided protection against invasion and metastasis as measured by transwell invasion/ migration assay in vitro. Our findings presented here indicate that HGF-mediated invasiveness and motility was significantly inhibited in HSulf-1-expressing clonal SCC012 cell lines compared to vector-transfected controls. This is the first report of HSulf-1 modulating such an important biological behavior. Although the precise mechanism by which HSulf-1 modulates this behavior is not completely known at present, we speculate that it is by disrupting the interaction between HGF and its cognate receptor c-Met by desulfating the sulfation pattern of its coreceptors HS-GAGs that is required for this interaction. This is probably a unique way by which a cancer cell is able to inhibit metastasis. Dong et al. (2001) demonstrated that HGF can promote the expression of angiogenesis factors in tumor cells through both MEK-and PI3K-dependent pathways in SCCHNs. However, they reported no significant differences in the total protein levels of p140 c-Met receptor and its downstream Erk and Akt kinases on HGF stimulation in normal keratinocytes and SCCHN tumor cells in culture. However, they observed a difference in the inducibility of c-Met phosphorylation between normal keratinocytes and SCCHN tumor cells. The difference was correlated to increased expression of IL8 and VEGF in SCCHN cell lines on HGF stimulation. The authors alluded to the presence of a suppressor protein in normal cells as one of the mechanisms to account for the difference in the activation of c-Met receptors in the normal cells. Based on the data presented here, we speculate that the presence of HSulf-1 could potentially represent one of those putative tumor suppressor proteins that is expressed in normal keratinocytes modulating the sulfation pattern of HS-GAGs, leading to the inactivation of c-Met protein in cells with HSulf-1. However, since phosphorylation of ERK and Akt leads to the activation of several downstream transcription factors in the nucleus, analysis of these factors in HSulf-1-expressing cells compared to normal keratinocytes on HGF stimulation may lead to the development of reagents for therapeutic intervention.
The functional results described above suggest that HSulf-1 is a cell surface enzyme that desulfates critical sulfated moieties in HS-GAG, thereby inhibiting the action of heparin-dependent growth factors at their receptors and diminishing their ability to activate the two major survival pathways, namely ERK-and Akt-mediated survival signaling in SCCHN. In the present study, using an in vitro motility/invasion assay, we were clearly able to demonstrate that in the presence of HSulf-1, cancer cells' ability to invade and probably metastasize is also severely curtailed. Since HGFmediated signaling is also important in inducing angiogenesis in SCCHN, studies to determine whether loss of HSulf-1 expression can modulate angiogenesis is currently underway.
Materials and methods
Cell culture
Three head and neck cancer cell lines, 012SCC, WMMSCC (Strome et al., 2002) and 015SCC, were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured as recommended by ATCC.
Drugs and reagents
Staurosporine (Sigma, St Louis, MO, USA) was dissolved in DMSO at a concentration of 1 mM, stored at À201C and subsequently diluted with serum-free medium before use. In all experiments, the concentration of DMSO did not exceed 0.1%. Cisplatin (Sigma, St Louis, MO, USA) was prepared immediately before use as a 1000-fold concentrated solution in DMSO.
Semiquantitative RT-PCR
Total RNA was extracted from three SCCHN cell lines using the RNeasy mini kit (Qiagen). cDNA synthesis was performed as described (Shridhar et al., 2002) . Reverse-transcribed cDNA (50-100 ng) was used in a multiplex reaction with Sulf-3F (5 0 -GAGCCATCTTCACCCATTCAA-3 0 ), Sulf-3R (5 0 -TTCCC AACCTTATGCCTTGGGT-3 0 ) and GAPDH-F (5 0 -ACCA CAGTCCATGCCATCAC-3 0 ) and GAPDH-R (5 0 -TCCAC CACCCTGTTGCTTGTA-3 0 ) in separate reactions to yield 760, 1260 and 825 bp products, respectively. The PCR reaction mixtures contained 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl 2 , 400 mM concentration of each primer for HSulf-1 and 50 mM for the GAPDH primers, and 0.5 U of Taq polymerase (Promega) in a 12.5 ml reaction volume. The conditions for amplification were as follows: 941C for 3 min followed by 29 cycles of 941C for 30 s, 581C for 30 s and 721C for 30 s in a Perkin-Elmer-Cetus 9600 Gene-Amp PCR system. The products of the reaction were resolved on a 1.6% agarose gel and photographed using the Gel Doc 1000 photo documentation system.
Establishment of stable transfectants
Exponentially growing 012SCC cells in 100 mm dishes were washed with serum-free medium and treated with a mixture containing 4 mg plasmid, 30 ml Lipofectamine and 20 ml Plus reagent (Invitrogen). After 3 h incubation, a medium with serum was added. G418 (400 mg/ml) was added 24 h later to select transfectants. Individual colonies were subsequently cloned using cloning cylinders. For controls, cells were similarly transfected with vector (pcDNA3.1 GFP-CT); and stable clones were selected.
Sulfatase assay
Confluent flasks of stable transfectants were washed in ice-cold PBS and lysed in SIE buffer (250 mM sucrose, 3 mM imidazole, pH 7.4, 1% ethanol) containing 1% (w/v) Nonidet P-40 and protease inhibitor cocktail (Roche Molecular Biochemicals). After the cells were sheared by passage through a 27-gauge needle, protein concentration was determined using the Bradford assay. The total cellular protein (100 mg) was preincubated with 10 mM estrone-3-O-sulfamate (Sigma Chemicals) at 371C for 1 h to inhibit steroid sulfatases. 4-MUS was then added to a final concentration of 10 mM in the presence of 10 mM lead acetate in a total volume of 200 ml. After incubation for 24 h at 371C, the reaction was terminated by addition of 1 ml 0.5 M Na 2 CO 3 /NaHCO 3 , pH 10.7. The fluorescence of the liberated 4-methylumbelliferone was measured using excitation and emission wavelengths of 365 and 450 nm, respectively.
Treatment with FGF-2 and HGF
To assess the role of HSulf-1 in FGF-2/HGF-mediated signaling, vector-transfected and HSulf-1 clones 1 and 2 were serum starved for 8-12 h, treated with diluent, 2 ng/ml FGF-2 (Sigma, St Louis, MO, USA) or 5 ng/ml HGF (Research Diagnosis Inc., Flanders, NJ, USA) for the times indicated in individual figures. Following treatment, cells were rinsed with ice-cold PBS, scraped from the dishes and lysed at 41C in SDS sample buffer without bromophenol blue. Protein concentrations were determined with bicinchoninic acid (Pierce, Rockford, IL, USA).
Immunoblotting
Equal amounts of protein (20 mg/lane) were separated by electrophoresis on an SDS gel containing a 4-12% SDS polyacrylamide gradient and electrophoretically transferred onto nitrocellulose. Blots were washed once with TBS-0.2% Tween 20 (TBST) and blocked with TBST containing 5% nonfat dry milk for 1 h at 201C. The blocking solution was replaced with a fresh solution containing 1 : 500 dilution of rabbit anti-phospho-ERK or anti-phospho-AKT-ser 473 (Cell Signaling Inc., Beverly, MA, USA). After overnight incubation at 41C, the blots were washed three times for 10 min each in TBS/0.1% (w/v) Tween 20 and incubated with horseradish peroxidase-conjugated secondary antibody in 5% milk/TBST at 201C for 1 h. After washing three times in TBST, the proteins were visualized using enhanced chemiluminescence (Amersham, Arlington Heights, IL, USA). The blots were stripped and reprobed with antisera that recognize total ERK or total Akt (Cell Signaling Inc., Beverly, MA, USA), and antityrosine antibody py20 and anti c-Met antibody (Santacruz Biotech).
Cell proliferation assay
Cell growth was assessed by MTT assay . In all, 3000 cells of HSulf-1 012SCC clones 1 and 2 as well as vector-transfected 012SCC were plated in 96-well plates, and incubated at 371C, 5% CO 2 . At 24, 48, 72 and 96 h, the medium was replaced with serum-free RPMI-1640 containing 0.2 mg/ml MTT and incubated for an additional 4 h. Following this procedure, the wells were drained and 160 ml of DMSO was added per well to solubilize the MTTformazan. After lightly vortexing the plate on an orbital shaker, the absorbance was read on a microplate reader (Bio Rad Model 3550-UV) using a measurement wavelength of 570 nm. Each individual experiment was performed at least three times and in six wells each. Stable clonal cells were seeded into 24-well plates at a density of 10 000 cells per well and incubated overnight in the complete medium. Next day, the medium was replaced with the serum-free medium for 6 h. Cells were then incubated with 0.5 mCi of [ 3 H]thymidine for 24 h. At the end of the incubation, the cells were washed three times with PBS-1 M thymidine and incorporated radioactivity was determined in TCA-precipitable fraction (Chien and Shah, 2001 ).
Invasion assay
Motility and invasion assays were performed in 6.5 mm diameter Transwell chambers (Costar, Cambridge, MA, USA) with a porous polycarbonate membrane (8.0 micron pore size). In both experiments, after 6 h serum starvation, the cells (10 4 /each well) were seeded on the upper side of the filter and either recombinant HGF (40 ng/ml) added to the lower chambers in serum-free media. For invasion assay, BD Bio Coat Matrigel Invasion chambers were used (BD Biosciences, Clontech; Bedford, MA, USA). After 4 h for motility assay or 24 h for invasion assay, cells on the upper side of the filters were mechanically removed. Cells migrated to the lower side were either fixed with 4% paraformaldehyde and stained with 0.25% coomassie blue for motility assays or with 100% methanol and stained with 1.0% methyl violet for invasion assay. The filters were photographed and the cells were counted.
Analysis of apoptosis
Apoptosis was quantitated by assessing the number of cells containing nuclear changes indicative of apoptosis (chromatin condensation and nuclear fragmentation) after staining with DAPI. HSulf-1-transfected 012SCC cells were seeded in 35-mm plates at a density of 2 Â 10 5 cells/well. After incubation at 371C for 24 h, the plates were washed and changed to serum-free medium. Staurosporine or cisplatin was added to a final concentration of 1 and 5 mM, respectively. After 5 h incubation for staurosporine and 24 h for cisplatin at 371C, DAPI was added to each well at a final concentration of 5 mg/ml. After 20 min incubation in the dark at 371C, cells were examined by fluorescence microscopy (Nikon Eclipse TE200; Nikon Corp., Tokyo, Japan) using excitation and emission filters of 380 and 430 nm. An individual blinded to the experimental conditions counted at least 300 cells in six different high-power fields for each treatment. Each treatment was repeated at least three times, performed in triplicate each time. The significance of differences between experimental variables was determined using the Student's t-test.
Detection of apoptosis by flow cytometry
HSulf-1-1-or vector-transfected 012SCC cells were collected by centrifugation from untreated control and staurosporinetreated cells. The cell pellets were washed twice in 41C buffer solution (PBS with 3% of heat-inactivated fetal bovine serum and 0.02% of sodium azide), and then were stained with 7AAD (50 mg/ml) for 15 min in the dark. The cells were then resuspended in 500 ml of PBS and analysed by FACScan (BD Bioscience, San Jose, CA, USA). The percentage of apoptotic cells was presented as % of 7AAD-positive cells in a total of 10 000 cells for each sample. The 012SCC vector cell line showed minimal apoptosis after treatment with staurosporine, whereas the 012SCC-HSulf-1-1 clone showed higher rate of apoptosis.
Statistical analysis
All data represent at least three independent experiments using cells from separate cultures and are expressed as the mean þ s.e.m. Differences between groups were compared using an unpaired two-tailed t-test.
